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http://www.biomedcentral.com/1472-6963/14/314STUDY PROTOCOL Open AccessProtocol for evaluation of the cost-effectiveness
of ePrescribing systems and candidate prototype
for other related health information technologies
Richard J Lilford1*, Alan J Girling2, Aziz Sheikh3,4, Jamie J Coleman2, Peter J Chilton2, Samantha L Burn2,
David J Jenkinson1, Laurence Blake2 and Karla Hemming2Abstract
Background: This protocol concerns the assessment of cost-effectiveness of hospital health information technology
(HIT) in four hospitals. Two of these hospitals are acquiring ePrescribing systems incorporating extensive decision
support, while the other two will implement systems incorporating more basic clinical algorithms. Implementation
of an ePrescribing system will have diffuse effects over myriad clinical processes, so the protocol has to deal with a
large amount of information collected at various ‘levels’ across the system.
Methods/Design: The method we propose is use of Bayesian ideas as a philosophical guide.
Assessment of cost-effectiveness requires a number of parameters in order to measure incremental cost utility or
benefit – the effectiveness of the intervention in reducing frequency of preventable adverse events; utilities for
these adverse events; costs of HIT systems; and cost consequences of adverse events averted. There is no single
end-point that adequately and unproblematically captures the effectiveness of the intervention; we therefore plan
to observe changes in error rates and adverse events in four error categories (death, permanent disability, moderate
disability, minimal effect). For each category we will elicit and pool subjective probability densities from experts for
reductions in adverse events, resulting from deployment of the intervention in a hospital with extensive decision
support. The experts will have been briefed with quantitative and qualitative data from the study and external data
sources prior to elicitation. Following this, there will be a process of deliberative dialogues so that experts can
“re-calibrate” their subjective probability estimates. The consolidated densities assembled from the repeat elicitation
exercise will then be used to populate a health economic model, along with salient utilities. The credible limits
from these densities can define thresholds for sensitivity analyses.
Discussion: The protocol we present here was designed for evaluation of ePrescribing systems. However, the
methodology we propose could be used whenever research cannot provide a direct and unbiased measure of
comparative effectiveness.
Keywords: ePrescribing, Health information technology, Cost-effectiveness, Adverse events, Bayesian elicitation,
Probability densitiesBackground
Provenance
This protocol concerns the assessment of cost-effectiveness
of hospital health information technology (HIT). The cost-
effectiveness analysis forms part of a National Institute
for Health Research (NIHR) funded research programme* Correspondence: r.j.lilford@warwick.ac.uk
1Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Full list of author information is available at the end of the article
© 2014 Lilford et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.to evaluate the implementation, adoption, effectiveness
and cost-effectiveness of ePrescribing systems as they
are introduced into a sample of hospitals in England
(RP-PG-1209-10099). Four hospitals will be studied –
before, during, and after implementation of an ePrescribing
system, as described in the application for funding
(RP-PG-1209-10099) [1-4]. Two hospitals are acquiring
systems with extensive decision support, while the other
two will implement systems incorporating only the mostLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lected from each site:
1. Qualitative data on the acceptability and adoption of
the system;
2. Quantitative data on prescribing safety;
3. Cost data.
In this paper, we describe the protocol for the cost-
effectiveness analysis that will follow data collection. For
reasons that have been described in a previous paper [5],
cost-effectiveness analysis of large scale service delivery
interventions raises issues that are not part of standard
Health Technology Assessment (HTA). We now describe
some of these issues in more detail.
Issues in evaluation of large scale service changes
Diffuse impact of generic health information technology
interventions
Implementation of an ePrescribing system is an ex-
ample of a generic intervention with diffuse effects,
spanning out over myriad clinical processes [5], in
contrast with more targeted interventions focussed on
a limited number of end-points. This crucial distinc-
tion is represented diagrammatically in Figure 1. Some
applications of HIT have narrow focus – mobile phone-
based decision support to improve compliance with
asthma treatment, for example [6] – and can be con-
sidered as examples of targeted service interventions.
On the other hand, a comprehensive ePrescribing systemPoint of 
Intervention
Intervening
variables†
Myri
pro
Generic
Intervention*
Figure 1 Representation of the widespread effects of a generic interv
†Sometimes referred to as organisation level outcomes to include morale,has many of the features of a generic service interven-
tion. It has a potential impact on work patterns (at the
system level) and it may affect a large number of clin-
ical processes (e.g. prescriptions) and contingent out-
comes (e.g. preventable adverse events) at the clinical
level. It is important to note that each adverse event
may be affected to a different degree by the interven-
tion and will be associated with a particular utility. This
is in contrast to typical HTA, which may have an effect
on one, or a limited number of, outcomes. The proto-
col thus has to deal with a large amount of information
collected at the system, clinical process and outcome
‘levels’.
Lack of contemporaneous controls
This study, in keeping with many in the service delivery/
quality improvement literature, is based on a before and
after design. A preferable controlled before and after de-
sign [7] (or randomised comparison) was not possible
within the funding envelope. The study therefore cannot
control for general temporal trends and is also subject to
selection effects given the non-experimental design. The
protocol thus needs to find a way to accommodate the
possibility of bias in estimates of parameters used to
populate the health economic model.
Integrating study results with evidence external to the
index study
Given the above uncertainties, decision makers will
want to ensure that parameters used in the estimation ofOutcome 1
Outcome 2
Outcome 3
ad of HO
cesses
Outcomes
ention. *First as intended and then as actually implemented.
staff attitude, knowledge, effect on patient flows etc.
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literature on HIT systems [8,9]. This cannot be achieved
by standard meta-analysis given the highly variegated na-
ture of the salient literature.Confronting the issues – epistemology of large-scale
service changes
Elsewhere we have suggested that generic service, and
many policy, interventions cannot be evaluated solely by
direct parameter estimates that have been so successful
for the evaluation of clinical treatments and for tar-
geted service interventions [10]. The framework out-
lined above provides a way forward in circumstances
where ‘knock-down’ evidence is elusive. It provides a
‘half-way house’ between fruitless striving for a clear
cut quantitative ‘answer’ and reverting to a completely
unquantified ‘interpretivist’ [11] or even ‘realist’ ap-
proach. We propose use of Bayesian ideas as a philo-
sophical guide (as proposed by Howson and Urbach)
[12] rather than a mathematical method to update a
prior probability density. This issue is explored further
in the discussion.
The scientific method can thus be conceptualised as the
process by which data are collected and analysed so as to
inform a degree of belief concerning the parameter(s) of
interest [13]. The data concerned may be of various types.
These diverse data types are assembled to inform a prob-
abilistic judgment.
The intellectual model we propose has the following
features:
1. Its epistemology is Bayesian, treating probability as a
degree of belief.
2. Quantitative study data are not used as direct
parameter estimates for use in models, but as
information to inform subjective estimates of
effectiveness.
3. Qualitative study data will also contribute to the
subjective estimates of effectiveness.
4. Subjective probability densities will be elicited from
groups of experts exposed to the above quantitative
and qualitative data, and also data from studies
external to the index study.
5. The densities will be pooled across experts for
use in health economic models (both for the base
case and to describe thresholds for sensitivity
analyses).
In summary, we will assemble both quantitative and
qualitative data, from different sources, to triangulate
any evidence of effectiveness or lack of effectiveness,
and establish parameters that summarise evidence of
effectiveness [10].Methods/Design
Overview of cost-effectiveness model
Evaluation of cost-effectiveness will proceed as follows [14]:
1. Evaluate effectiveness in reducing the frequency of
preventable adverse events;
2. Assign utilities for these adverse events;
3. Calculation of expected health benefit;
4. Determine costs (fixed and recurrent) of procuring,
implementing, operating and maintaining HIT
systems and model the cost consequences of adverse
events averted;
5. Calculation of cost-effectiveness.
The first two quantities (effectiveness in reducing ad-
verse events, and utilities) are used to calculate health
benefit (assuming that this cannot be captured directly
through a quality of life measurement – see below).
Component 4 allows net costs to be estimated. Costs
and benefits can then be consolidated in a measure of
incremental cost utility or cost benefit. An overall frame-
work for our proposed evaluation is given in Figure 2.
The perspective of the evaluation is that of the health
services, at least in the first instance – a point to which
we return.
Evaluation of effectiveness
Consideration of quantitative end-points
There are four (non-exclusive) end-points that may be
used in measurement relating to effectiveness:
1. Generic quality of life;
2. Adverse event rates (including mortality);
3. Error rates;
4. Triggers (for errors or adverse events).
None of the above end-points are unproblematic. We
now discuss each to determine which are more suitable
in the context of this study.
Generic quality of life A generic measurement of qual-
ity of life, using a measurement tool such as the SF36
[15], is an attractive option because such a measurement
(when combined with death) consolidates all the various
adverse events that the intervention is designed to pre-
vent. This end-point thus gets around the problem that
each adverse event has its own utility and may be af-
fected differentially by the intervention. The problem,
however, is that prescribing errors make only a very
small contribution to generic quality of life since less
than 1% of patients suffer a preventable medication-
related adverse event during a single hospital stay and
the majority, as we shall see later, are minor and short-
lived [16]. In short, any ‘signal’ would be lost in ‘noise’; a
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Figure 2 Framework for the evaluation.
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provement had occurred.
Medication-related adverse events Again, the value of
this end-point is limited by issues of statistical power as a
result of the ‘ceiling’ for improvement in preventable
events of approximately one percentage point [17], as
mentioned above. The sample size calculations in Table 1
show that a very large number of cases would have to be
examined to avoid a high risk of a false null result in de-
tecting preventable adverse events. Detecting medication-Table 1 Sample size calculations for detection of
reductions in adverse event rates
Risk ratio Power (%) Sample size (total)
0.6 80 16,556
0.7 80 30,716
0.8 80 71,988
0.6 90 40,676
0.7 90 41,294
0.8 90 95,702
Sample size calculations for detection of reductions in preventable adverse event
rates in a simple comparison of two equally sized groups of patients – assumes a
two-tailed alpha of 0.05 (without continuity correction) and a control probability of
1%. Results from STATA v12.0.related adverse events with adequate specificity for use in
a comparative study requires direct observation or case-
note review, meaning it would be impossible (or at least
ruinously expensive) to conduct an adequately powered
study on this basis.
Prescribing error rates Prescribing errors are much
more common than error-related (i.e. avoidable) ad-
verse events; the baseline error rate is about 5% [18],
and hypothesised reductions in these errors of 30%
(two percentage points) or more are in line with those
found in the literature [8,9]. This end-point therefore
yields more manageable sample size requirements
(Table 2). Samples sufficient to detect a 30% improve-
ment with 80% power are feasible under the funding
envelope of the study. However, this end-point is far
from perfect because:
1. Errors are surrogates for adverse events. It is therefore
necessary, in any cost-effectiveness analysis, to infer
adverse event rates from error rates – a step that
introduces further uncertainty.
2. Error rates are associated with considerable
measurement error [19], and detection can be
affected by learning effects, fatigue [20], and
conceivably also by use of a computer.
Table 2 Sample size calculations for detection of
reductions in error rate
Risk ratio Power (%) Sample size (total)
0.6 80 3,210
0.7 80 5,940*
0.8 80 13,888
0.6 90 4,230
0.7 90 7,862
0.8 90 18,456
*Similar to proposed sample in this study.
Sample size calculations for detection of reductions in error rate; baseline error
rate 5% and other assumptions, as in Table 1.
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perpetrated [21], and so a study based on a limited
sample is likely to underestimate effects of an
intervention on rare, but egregious, errors.Trigger tool methods Triggers are based on evidence
suggesting that a preventable adverse event might have
occurred (e.g. administration of vitamin K or anti-
narcotics to reverse a putative overdose of warfarin or
morphine respectively). The triggers are selected on the
basis that they can be easily ascertained from existing
data systems – it is easy to search the pharmacy database
for use of the above antidotes, for example. Such triggers
can be useful in quality improvement programmes where
the IT system remains stable over a period where a non
IT-based safety intervention is introduced [22]. They are
likely to yield a biased result, however, when the IT sys-
tem is both the intervention of interest and used in col-
lection of end-point data. Furthermore, triggers are not
only non-specific, but insensitive [23]. This is because
only a small proportion of all medication-related adverse
events show up on a trigger tool system.Selection of quantitative end-points
It can be seen from the above analysis that there is no
single end-point that adequately and unproblematically
captures the effectiveness of the complex intervention
that we have been commissioned to study. Following
discussion with the programme Steering Group we de-
cided to reject two of the above four possible end-points.
Trigger tools were rejected on the grounds that while
they are useful in quality control systems within a stable
platform, they are likely to be a highly unreliable (biased
and imprecise) tool for scientific measurement of the ef-
fectiveness of a HIT system. Generic quality of life ques-
tionnaires were rejected on the grounds that they could
not detect improvement among the small proportion of
patients that suffer an avoidable medication-related ad-
verse event.We will measure error rates and adverse events as the
‘least bad’ options in this study. Error rates will be mea-
sured as described in detail elsewhere [24]. In brief, a
specified list of 80 errors with potentially serious conse-
quences has been identified by a consensus technique.
[25] These errors are reasonably common and by con-
centrating on a limited number we believe we can iden-
tify them with high sensitivity irrespective of the
‘platform’ in use – i.e. irrespective of whether the com-
puter system has been deployed. To mitigate measure-
ment error, observers will be trained, and to reduce the
effect of prescribing systems on measurement the re-
viewers will be on site with access to all prescribing infor-
mation, whether held on computer or recorded on paper.
In this way we plan to make the data collection task as
independent as possible from the intervention. We in-
tend to identify errors by examining every prescription
within a sample of consecutive patients, as used in many
other studies [18].
The observers will also record adverse events that
come to light during the study. Each patient case note
will be reviewed for adverse events, which will then be
examined in detail to determine whether, on the balance
of probabilities, they were preventable.
Illustrative modelling of adverse events from errors
Errors are important only insofar as they portend ad-
verse events. In order to illustrate the pathway between
errors and preventable adverse events, we will model ex-
pected reductions in adverse events from (any) reduc-
tions in error rates. Since doing so for all 80 errors on
the above list would be a laborious and expensive
process, we shall do so for exemplars across four error
classes – drug interactions, allergy, dose error and
contra-indications. Within these classes we have selected
errors for which information to populate causal models
is available in the literature – a point taken further in
the discussion. Further details on this method are given
in Additional file 1. Patients are exposed to the risk of
error and hence of an adverse event when attending hos-
pital and receiving a prescription. As these are mainly
one-off prescriptions, decision trees will be used to
model the risk of adverse events. For each of the illustra-
tive errors chosen, the probability of contingent adverse
events will be modelled on the basis of information in
the literature. Markov chains will be used when one ad-
verse event may lead to another – for example deep ven-
ous thrombosis that may lead to pulmonary embolism
that, in turn, may lead to death. In this way, we will
compute the headroom for reductions in adverse event
rates related to certain specific errors, i.e. the reduction
in adverse event rates that would be expected if the causal
errors could be eliminated. The results will be used to as-
sist expert judgement within the elicitation of subjective
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is that the results of this modelling exercise, with respect
to just four errors, will help experts to mentally ‘calibrate’
their subjective probability estimates, with respect to error
in general. More specifically, we think that it will mitigate
heuristic biases, such as over-confidence and anchoring,
itemised by Kadane and Wolfson [26].
Classifying adverse events
As stated above, the purpose of the elicitation exercise is
to estimate reductions in adverse events. We will have to
deal with the fact that there are a very large number of
different preventable adverse events. It cannot be as-
sumed that an intervention will affect all events equally.
Moreover, each event is associated with its own mean
utility. Ascribing a single probability and utility to cover
all adverse events is too crude. On the other hand,
ascribing a probability and utility to each and every
event detected in the study or inferred from errors
would be a logistically taxing process and would omit
certain rare, but notorious, events such as daily rather
than weekly methotrexate administration. Our approach
to this problem builds on a previous study by our group,
where adverse events were classified according to severity
and duration [14]. Classification systems that have been de-
scribed in the literature are explicated in Table 3.
We shall use the four category system (i.e. dead, per-
manent disability, moderate disability, minimal effect)
proposed by Hoonhout and colleagues [28]. We have se-
lected this system for two reasons. First, it has the smal-
lest number of categories, and will therefore be the least
tedious to implement when probabilities and utilities are
elicited. Second, this is the only system for which the
costs associated with preventable adverse events in
each category are available (Table 4). In subsequentTable 3 Classification systems for adverse events, with preval
given category)
Forster et al. [27] Brennan et al. [17]
Event category Proportion
in category
Event category Proportion
in category
Death 0 Death 0.136
Permanent disability 0.03 Permanent impairment,
>50% disability
0.026
Permanent impairment,
≤50% disability
0.039
Readmission 0.21 Moderate impairment,
recovery >6 months
0.028
A&E visit 0.11 Moderate impairment,
recovery 1–6 months
0.137
Physician visit 0.14 Minimal impairment,
recovery <1 month
0.634
No extra use of health
service
0.51calculations we will make use of the probability of each
category of adverse event arising as a result of treatment
given in hospital. This is given by the product of the pro-
portions of adverse events in each category (Table 4) and
the prevalence of all preventable adverse events (i.e. 0.01
[1%] as referenced above).
Qualitative data
As stated in the introduction, the full evaluative study
includes a qualitative component. As discussed in the
section on epistemology, the qualitative data are used to
inform Bayesian elicitation alongside quantitative data.
In the case of ePrescribing systems, organisation-level
data, such as the success of implementation and staff atti-
tude, have a bearing on effectiveness [1-4]. A qualitative
finding that these elements are positive would reinforce a
statistical observation that medication errors had been
reduced, and yet this finding would be difficult to incorp-
orate into an objective analysis. Our approach provides
a way out of this conundrum by providing quantitative
parameter estimates (for use in a decision model) that ef-
fectively combine qualitative and quantitative information
through the elicitation of probability densities.
Eliciting subjective probability densities
We propose to elicit subjective probability densities for
an effectiveness parameter for each of the Hoonhout
sub-groups. As discussed before, we are not adhering to
the usual paradigm, whereby a prior is elicited and then
updated in a statistical manner by means of direct com-
parative data. Rather, we wish to assemble all relevant
data, both from the index study and from external
sources, and then elicit subjective probability distributions
from experts [31]. The sequence of events is summarised
in Figure 3.ence figures (proportion of total adverse events in
Hoonhout et al. [28] Yao et al. [14]
Event category Proportion
in category
Event category Proportion
in category
Death 0.078 Death 0.05
Permanent
disability
0.047 Permanent impairment,
>50% disability
0.02
Permanent impairment,
≤50% disability
0.03
Moderate disability 0.617 Moderate impairment,
recovery >6 months
0.10
Moderate impairment,
recovery 1–6 months
0.30
Minimal effect 0.257 Minimal impairment,
recovery <1 month
0.50
Table 4 Classification of preventable adverse events that we propose to use in this study*
State Proportion Utility Mean duration,
L (years)
Cost,
2009 (€)
Comments Example
Death 0.078 0 3 3,831 Duration here is expected mean
survival without the event, as
estimated as weighted average
from Zegers et al. [29]
Vincristine administered by
intrathecal route.
Permanent disability 0.047 To be determined 6 6,649 Costs exclude long-term care.
No data on mean duration, but
a given adverse event is more
likely to be fatal in an older
person, so mean survival
assumed to be a little longer
than life years lost in those
who died.
Haemorrhagic stroke in patient
prescribed warfarin and
macrolide antibiotics.
Moderate disability 0.617 To be determined 0.2 5,973 Duration ≤6 months in 70% of
cases (Baker et al. [30])
Pulmonary embolism in large
patient given standard
(inadequate) dose of heparin.
Minimal effect 0.257 To be determined 0.05 2,979 Transient urticarial rash in known
allergic patient given penicillin.
*Based on Hoonhout et al. [28]
Form expert group
Present evidence dossier–review, qualitative data, 
quantitative ‘effectiveness’ data, and cost data
Discuss each type of evidence in series
Discuss implications for effectiveness estimates
Elicit Probability Densities individually
Break (Pool densities)
Further discussion
Final probability elicitation
Final mathematical pooling
Formal description of elicitation process
from review of recording
Figure 3 Sequence of events for elicitation of Bayesian
probability densities.
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will have been made in four hospitals; two where the IT in-
cludes advanced decision support, and two incorporating
more rudimentary clinical algorithms. Eliciting probability
densities for all four hospitals would be a tedious process.
We will therefore elicit probabilities for just one high sup-
port hospital (selected at random), but the experts will be
exposed to data from all hospitals. This will, we believe,
provide an opportunity for nuanced data interpretation –
for example if improvement is similar across high and low
decision support hospitals, this will moderate cause and ef-
fect interpretations in the former group.
In line with good practice, the group from whom the
densities will be elicited will be selected on the grounds that
they are knowledgeable about the domain of enquiry but
have no stake (emotional or other) in the results [32,33].
The expert members of the International Programme
Steering Committee (IPSC) meet this requirement and
we will therefore elicit probability densities from this
constituency. Before attending for the elicitation exercise,
participants will be sent a ‘dossier’ made up as follows:
1. Systematic review of salient evidence based on
updated version of our previous review [8];
2. Results of the qualitative investigations in the four
participating hospitals;
3. Before and after comparison of error rates across the
four hospitals;
4. Before and after comparison of adverse event rates,
both directly (but imprecisely) measured and
modelled from the four selected error rates.
The group will discuss the above evidence and its limi-
tations before taking part in the elicitation process.
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the above four data-types in series, before discussing what
they may mean, and thereby synthesising evidence and ar-
gument. Probability densities will be elicited separately for
each Hoonhout category. These probability densities will
then be combined across experts.
The elicitation questionnaires have been informed by
our previous experience [14,34,35], and are included as
Additional file 2. In designing a questionnaire a number
of decisions must be made [33]:
1) Whether to include a training exercise. In our case
the respondents are familiar with Bayesian
principles, so we have omitted this step.
2) Whether to ask respondents to assign probabilities
to effect sizes of various magnitude (fixed interval)
or to assign magnitudes corresponding to various
probabilities (variable interval). Based on our
previous experience we will use the first method
only, not wishing to tire the experts (Additional
file 2). The fixed interval method is often
performed using the ‘chip and bin’ or ‘roulette’
method, which involves asking the expert to assign
chips to various bins (into which the variable has
been divided up) to build up their distribution of
beliefs. Rather than using discrete chips we will ask
the experts to mark a line to indicate the relative
height of their density for that bin – a method
that has worked well in the past (see figure in
Additional file 2) [35].
3) Whether to elicit an effect size for the intervention
(as Spiegelhalter has done) or separate estimates for
control and intervention patients (as O’Hagan
recommends and as we have used previously) [36].
The latter avoids the need to make assumptions
about independence between baseline (control) rates
and the intervention effect size, but we will select
the former on the grounds that we have found it
(anecdotally) to be more intuitive for clinicians, who
are familiar with data presented in this way. We will,
however, ask about percentage change (on a relative
risk scale), which avoids experts having to think
about small probabilities [37].
4) Whether to elicit individual subjective probability
densities with a view to aggregating them or use a
behavioural approach to aggregation and conduct a
group elicitation [33]. We plan to use the first
method, but the elicitation will be preceded by
group discussion and an iterative process will be
used, as described above.
5) Whether to use software or paper to record elicited
data. We plan to replicate the data capture
questionnaire on software to avoid the need for a
two stage procedure.After the questionnaires have been completed, we will
pool the elicited distributions. We will then present the
individual elicited (anonymised) probability distributions
and the pooled probability distribution back to the group.
In this way each member of the group will be able to re-
flect on their opinions and have a chance to revise them in
the light of the opinions of other members of the group
and the corresponding group consensus. Provided that per-
mission is granted by all participants, the elicitation meet-
ings will be video recorded for subsequent enquiry into the
process of elicitation itself. A separate protocol will be writ-
ten for this exercise.
Assigning utilities
Utilities are not available for adverse events as a whole
or in groups. They are seldom available for the individ-
ual events, death apart, unless they are naturally occur-
ring disease states (such as deafness or kidney failure)
that can also result from medication error. Moreover, it
is the adverse event category for which we need adverse
events in this study. We will obtain utilities through two
separate methods:
1. We will select an archetypal example (Table 4) of an
adverse event that may result from medication error
within each category and for which utility estimates
are available in the literature (severe gastro-intestinal
bleed resulting from a prescription of non-steroidal
anti-inflammatory drugs to a patient already on
warfarin, for example).
2. We will elicit utilities for the Hoonhout groups
(Table 4) using the time trade-off method [38]. We
will again ask the members of the IPSC to take part
in this exercise since we believe it would be very
difficult for members of the general public to
conceptualise groups of disease states. We cannot
be certain that the people who are experts in the
subject of medication error will find this exercise
satisfactory, and it is for this reason that we include
the first method above – it forms an insurance policy,
as well as data for possible sensitivity analysis.
Calculation of health benefit
When the above data have been collected the health
benefit in Quality Adjust Life Years (QALYs) per hospital
admission will be calculated as a sum over the four cat-
egories of the form:
X4
i¼1
RRi  pi  Ui  Li
Where for each category (i = 1,2,3,4)
RRi is the relative reduction in adverse event rate elicited
from the expert group;
Lilford et al. BMC Health Services Research 2014, 14:314 Page 9 of 12
http://www.biomedcentral.com/1472-6963/14/314pi is the pre-intervention prevalence of the event (i.e.
overall prevalence x proportion from table 4);
Ui is the estimated loss of utility associated with the
event;
Li is the time period (in years) over which the loss of
utility is experienced (Table 4).
The above calculation assumes that within the adverse
event groupings, change in probability of event occur-
ring, severity of event, and length of adverse event are
all assumed to be independent.
Determining net costs
There are three broad types of cost associated with HIT
system:
1. Equipment costs (purchase and maintenance of
hardware and software);
2. Training costs and effect of HIT use on staff time;
3. Costs contingent on changes in adverse event rates.
The first category above will be ascertained by document
retrieval on site, backed up by interviews with vendors.
Categories of staff time that may be affected (positively and
negatively) by installation of an HIT system will be derived
from qualitative interviews, and quantified by means of
time and motion studies that will be described elsewhere.
The third cost category will be calculated per patient using
the formula:
X4
1
RRi  pi  Ci
Where Ci is the cost of the adverse event class after
Hoonhout et al. [28] The figures given by Hoonhout
et al. will be converted from Euros to Pounds Sterling,
converted for purchasing power parity through a Gross
Domestic Product (GDP) Purchasing Power Parity (PPP)
conversion factor [39], and updated to 2014 rates by ap-
plying the Hospital and Community Health Service
(HCHS) Pay and Price Inflation Index (a weighted aver-
age of two separate inflation indices, the Pay Cost Index
(PCI) and the Health Service Cost Index (HSCI).
Calculation of cost-effectiveness
QALY gains will then be calculated for hospitals with
20,000, 35,000 and 50,000 admissions per year. Upfront
hardware costs will be amortised over 20 years, applying
a discount rate of 3.5%, in line with National Institute
for Health and Care Excellence (NICE) guidance [40].
Annual costs of maintaining a computer system and
employing staff will be added to the amortised capital
expenditure. Cost savings from adverse events averted
will be subtracted to yield a global net cost at the level
of the health service (not individual hospital). This will
enable us to calculate the incremental cost-effectiveness
ratio (ICER):ICER ¼ Total costsð Þ  Total QALYs gainedð Þ
We will also express QALY gain as Expected Monetary
Benefit (EMB):
EMB ¼ QALYs gainedð Þ  λ
Where λ is societal willingness to pay for one QALY –
assumed to be £20,000 in the base case. This will also
enable us to express the result as the Expected Net
Benefit (ENB):
ENB ¼ EMB − Δ costs
A problematic sensitivity analysis will then be per-
formed by pooling the effectiveness distribution and a
cost-effectiveness acceptability curve constructed to show
the likelihood that the intervention is effective as a func-
tion of the threshold, including a zero threshold where it is
cost-releasing.
Discussion
The epistemology of our proposed evaluation
The study is designed to deal with a frequent and justi-
fied criticism of many evaluations of information tech-
nology applications – namely that they do not, and
cannot, capture all salient end-points [41]. An evaluation
of this technology cannot ignore these end-points just
because they cannot be captured objectively in numer-
ical form. Health economic models require input param-
eters even if these cannot be measured directly; they
must be assessed in some other way. We have previously
approached this problem by capturing the necessary esti-
mates in the form of a Bayesian probability distribution.
In this study any observed reduction in errors and ad-
verse events will be used to inform an elicited subjective
estimate of the putative reduction in relative risk of ad-
verse events as a whole, rather than to provide a direct
estimate of that parameter.
Where a scenario can be described by a decision
model, any pragmatic choice can be reverse-engineered
into a subjective belief about the likely value(s) of some
critical parameter or parameters. Consider a decision
maker who wished to reduce adverse events. Choice of a
prescribing system that claimed to have this effect would
imply the decision maker believed the cost of the sys-
tem was outweighed by health benefit associated with
avoided events. But choices must frequently be made in
the light of imperfect information about such parameters.
Then it would be reasonable that a group of potential de-
cision makers come together to discuss whether the sys-
tem should be adopted, having weighed up all the pros
and cons – i.e. all forms of evidence. This approach might
well be applauded where no definitive objective answer
could be obtained. What we envisage is to engage experts
at a more basic level by unpicking their beliefs about the
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tudes to the decision itself. Such beliefs, expressed as sub-
jective probability densities, can then be combined with
exogenous parameters (such as the cost-effectiveness
threshold) to forward-engineer a rational approach to the
decision itself in a particular policy environment.Modelling causal pathways to inform elicitation exercises
A rather unusual component of our protocol is the
“calibration” method, whereby we propose modelling
adverse events from just four error types. Two issues
arise – whether such an exercise is helpful, and how, if
helpful, examples should be selected. On the first point,
our reading of the psychological literature is that
methods that help the mind to decompose complex tasks
are normative (mitigate heuristic biases). On the second
point, we had much debate in committee over the selec-
tion of topics. We are aware of the potential criticism
that errors associated with literature on potential harms
may be a biased subset of the errors they are intended to
represent. Depending on the size of this bias, this exer-
cise could increase rather than mitigate bias. We would
value feedback from the academic community on these
points.Unresolved issues
One important limitation of the study is that it is based
on health service costs and benefits, rather than a so-
cietal perspective, especially those resulting from per-
manent harm. The estimate of Hoonhout et al. of cost
implications of adverse events took this narrower per-
spective, and also did not include cost consequences
over the long term [28]. The model could be extended
to take these longer term and broader societal impacts
into account given the necessary parameter estimates.
However, obtaining credible estimates for these param-
eters would be a research project in its own right.
Unless such figures are published between now and
publication of the results of our model, we plan to
leave long-term benefits out of the model and simply
qualify our results as conservative (i.e. a likely under-
estimate of cost-savings).
Any classification system is a compromise between de-
tail and practicality. The system used by Hoonhout
et al., to classify adverse events, conflates severity and
duration, while that of Brennan et al. [17] and of Yao
et al. [14] classify adverse events according to both di-
mensions (Table 3), producing six-point scales. However,
we are mindful of the requirement to elicit both prob-
abilities and utilities from our respondents and avoid
elicitation fatigue. For this reason, and also because costs
are available for it, we have proposed Hoonhout’s four-
point scale, at least for the time being.The wording of questions is important in eliciting
probability densities. Service delivery interventions are
context dependent [42] and it is therefore important to
be clear about context in elicitation. We therefore make
it clear that the context relates to those of the National
Health Service (NHS) at the time of the intervention. A
more controversial point concerns elicitation for just one
of the four hospitals in the study of four cases. Certainly, to
obtain separate distributions for each hospital would create
elicitation fatigue, but densities could be elicited for groups
of institutions – in this case adopters of high versus low
level decision support. However, this risks lack of clarity
about precisely what the parameter relates to, so our in-
terim solution is to focus on a particular hospital. As in
any research study, decision makers will need to exercise
judgement when extrapolating across time and place.Conclusion
We present a method to deal with the “inconvenient
truth” [5] that occurs when complex generic service deliv-
ery interventions must be assessed for cost-effectiveness.
The method we propose here includes first, an assembly
of relevant information on multiple end-points and con-
textual factors from within and outside of an index study.
Instead of using this information to directly inform a deci-
sion, it is used to generate probability densities for the pa-
rameters of interest – in this case reductions in adverse
events, by category, resulting from deployment of IT. A
process of deliberative dialogues follows, so that experts
can “re-calibrate” their subjective probability estimates in
the light of, for example, factors they may have over-
looked. A consolidated prior assembled from the repeat
elicitation exercise can be used to populate a health eco-
nomic model, along with salient utilities. The credible
limits on these densities can define thresholds for sensi-
tivity analyses.Ethics
The National Research Ethics Service (NRES) Committee
London – City and East were consulted regarding ethical
approval, and deemed a full ethical review by a NHS
Research Ethics Committee unnecessary.
In line with basic ethical principles, we will ensure that
all experts who undertake the elicitation questionnaire
will participate voluntarily with informed consent and
can withdraw from the study at any time.Additional files
Additional file 1: Protocol for evaluation of the cost-effectiveness
of ePrescribing systems. Additional file 1. Key prescription errors that
may be prevented using an electronic prescribing system.
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